Ana Valente, MD
Gynecologic Oncology · Oklahoma City, OKNPI 1871911685
Payments from drug & device makers
What this record shows
12 manufacturers reported payments, led by Intuitive Surgical at 52.4% of the total. Reporting peaked in 2022 at $1,149 and has fallen 71.9% since, to $323 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in OK, where the typical reported total is $3,072.
Across 21 payments — averaging $93.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- GSK$264
- Merck$197
- AbbVie$139
- Eisai Inc.$100
- AstraZeneca$85
- plus $150 from 6 others
What the payments were for
- Food & beverage$87945%
- Education$1,08555%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $1,029 |
| GSK | 4 | $264 |
| Merck | 4 | $197 |
| AbbVie | 3 | $139 |
| Eisai Inc. | 1 | $100 |
| AstraZeneca | 1 | $85 |
| Tempus AI, Inc | 1 | $30 |
| Genmab U.S., Inc. | 1 | $29 |
| Caris MPI, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Myriad Genetic Laboratories, Inc. | 1 | $27 |
| Clovis Oncology, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$1,000
- JEMPERLI$227
- KEYTRUDA$116
- ZEJULA$107
How this compares
$1,964 in reported general payments places this provider in the 45th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Medroxyprogesterone Acetate | 12 | $275 |
| Dexamethasone | 31 | $174 |
| Prochlorperazine Maleate | 19 | $127 |
| Olanzapine | 24 | $54 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Oklahoma City
- Debra RichardsonOklahoma City$97K
- Camille JacksonOklahoma City$35K
- Tara CastellanoOklahoma City$26K
- Joan WalkerOklahoma City$11K
- Christina WashingtonOklahoma City$9K
- Elizabeth EvansOklahoma City$3K
- Lauren DockeryOklahoma City$3K
- Nicole MinaltOklahoma City$2K
- Jacqueline BohnOklahoma City$1K
- Aleia CrimOklahoma City$862
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.